Skip to main content

JAK/TYK2

      RT @AurelieRheumo: EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer
      1) If remission, initiate ta
      1 year 6 months ago
      EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer 1) If remission, initiate targeted therapy w/out delay 2) Prefer anti-cytokine bDMARDs if Hx solid cancer 3) B cell depleting therapy if Hx lymphoma 4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1
      RT @AurelieRheumo: New benefit/risk outlook 👀 on ORAL surveillance
      2 subgrps:
      🟢RA w/ no previous Hx of atheroscler
      1 year 6 months ago
      New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U
      ×